{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Austria Diagnostics & Research news", "home_page_url": "https://sharemaestro.com/newsreel/at/healthcare/diagnostics-research/", "feed_url": "https://sharemaestro.com/newsreel/at/healthcare/diagnostics-research/feed.json", "description": "Latest Diagnostics & Research company headlines from Austria, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:cf8f8e2e6dfcace0e6fe8f5af3d77937351bfb2e3ce92051161d225e3ad41307", "url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "external_url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "title": "Envetec Appoints Patrick S. Jones as Independent Director", "content_text": "Envetec Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec's global expansion Patrick S. JonesPatrick S. Jones, President of Thermo Fisher Scientific's Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life sciences, today announced the appointment of Patrick S. Jones, president of Thermo Fisher Scientific", "date_published": "2026-08-14T07:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:bc28a49ce510ac5a9ebb23de8819886b9b24d2f299e044b25775aab004164d6e", "url": "https://finance.yahoo.com/healthcare/articles/fda-clearance-qiastat-dx-bloodstream-121034829.html", "external_url": "https://finance.yahoo.com/healthcare/articles/fda-clearance-qiastat-dx-bloodstream-121034829.html", "title": "Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?", "content_text": "Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. On August 10, 2026, the company also secured U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, moving its QIAstat-Dx platform into bloodstream infection diagnostics and reinforcing its effort to offer a broad infectious disease testing menu on one integrated system. We'll now e", "date_published": "2026-08-13T12:10:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QGE4"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QGE4", "name": "QIAGEN NV", "sentiment_url": "https://sharemaestro.com/sentiment/85c6bce5-f3f8-4e04-a5b1-0f8521931b52/"}]}}, {"id": "source:2dd4be49feba281b049e08a85747f7bdd52c55d23b81c7a35a04371f8a8f139b", "url": "https://finance.yahoo.com/healthcare/articles/strong-q2-2026-results-cardiac-021011441.html", "external_url": "https://finance.yahoo.com/healthcare/articles/strong-q2-2026-results-cardiac-021011441.html", "title": "Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?", "content_text": "IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We'll now examine how the new Catalyst proBNP Test and raised 2026 guidance may reshape IDEXX's broader investment narrative. Capitalize on the AI infrastructure su", "date_published": "2026-08-13T02:10:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IDXX"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IDXX", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec684ca1-5592-42c0-87f1-2957473896e9/"}]}}, {"id": "source:4de41d510eb6b85ba6b7bab47e5d874ee9668bafd394ff2f37adc57dcbc6d752", "url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "external_url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "title": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)", "content_text": "LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize ", "date_published": "2026-08-12T23:16:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:514e128ebb8254b2e7833258dba6fdd75fb5811bfb18edc60a79a42420c9a8e5", "url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "title": "LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a", "date_published": "2026-08-12T22:09:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:029b930f20a105a95eaa12cd975b6a874a0df5533dd2b17096e2a683ed2b555d", "url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "title": "Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist", "content_text": "The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and pharmaceutical markets. The investment reflects Astorg's focused healthcare strategy and distinctive approach to complex transactions, combining deep sector expertise, and a strong track record of operational value creation. Dirk Bontridder has been appointed Chief Executive Officer to lead the company through its next stage of growth, in partnership with Astorg. LUXEMBOURG & NEW YORK & PARIS, August 12, ", "date_published": "2026-08-12T12:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:d7ffec6e6848b736b4a9bdaa99baad8cd5c62764060ba7d18bbb63b3adaa648a", "url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "external_url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "title": "Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030", "content_text": "Company Logo Accelerating momentum across major industry heavyweights\u2014highlighted by Thermo Fisher Scientific's Q2 2026 revenue beat, Hamamatsu Photonics' launch of its dedicated Lasers & Fibers Business Unit, and BD's $4.98 billion Q3 performance\u2014is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics MarketBiophotonics Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"Biophotonics - A G", "date_published": "2026-08-12T11:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:1bf1a09d8e5ed239af1711d1be1d1d1ea675858affeadb586e3289c88f63c03f", "url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "title": "Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?", "content_text": "Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter growth engine: the real-world data business tucked inside its lab-services empire, far from the instruments most investors picture when they hear the name.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Growth Machine Bu", "date_published": "2026-08-11T21:20:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:33df7ded49c2f5f4575b1482e58d3b2d84fa1b5dc39c58c6f5ec5b473a7578ca", "url": "https://finance.yahoo.com/markets/stocks/articles/talen-energy-tln-raised-guidance-192349215.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/talen-energy-tln-raised-guidance-192349215.html", "title": "Talen Energy (TLN) Raised Guidance In August, So Why The Loss?", "content_text": "On August 5, Talen Energy (NASDAQ:TLN) posted a net loss for the second quarter, and yet the same release raised the company's full-year 2026 outlook and lifted its expectations for 2027 and 2028. That looks like a contradiction until you separate the accounting from the cash. One line tells you what hit the income statement. The other tells you where the business is actually headed.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Flywheel Strategy Gaining Speed Adjusted EBITDA came in at $374 million for the quarter, up sharply from $90 million a year earlier,", "date_published": "2026-08-11T19:23:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:8c3210a2efed1a915d0aaa5cca0de5722694e6134cc5a4c6b87354a602e65942", "url": "https://finance.yahoo.com/markets/stocks/articles/idexx-idxx-q2-2026-earnings-162815512.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/idexx-idxx-q2-2026-earnings-162815512.html", "title": "IDEXX (IDXX) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, and welcome to the IDEXX Laboratories Second Quarter 2026 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Mike Erickson, President and Chief Executive Officer; Andrew Emerson, Chief Financial Officer; and John Ravis, Vice President, In", "date_published": "2026-08-11T16:28:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IDXX"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IDXX", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec684ca1-5592-42c0-87f1-2957473896e9/"}]}}, {"id": "source:a69cae4db5e2b442f47ba0efd1131089a9b8f487f65c34896986bddbf8f32189", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-illumina-145200153.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-illumina-145200153.html", "title": "The Zacks Analyst Blog Highlights Illumina, Qnity Electronics and nVent Electric", "content_text": "For Immediate Release Chicago, IL \u2013 August 11, 2026 \u2013 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Illumina ILMN, Qnity Electronics Q and nVent Electric NVT. Here are highlights from Monday's Analyst Blog: More Intervention in Japanese Yen? Global Week Ahead What happens in this Global Week Ahead? No time for a break. Even in the middle of August, there is plenty of market news to watch: \u00b7 There's possi", "date_published": "2026-08-11T14:52:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "ILMN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ILMN", "name": "Illumina, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6f300b41-c30f-4595-b5f5-54fc4a511ae6/"}]}}, {"id": "source:5c6a39778f3067627cb7bc3a54e6b94141910a440f639598b5d84d1518ddcad7", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "title": "Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson\u2019s Precision Medicine", "content_text": "Olink\u2122 Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approximately 5,500 research samples were analyzed using Olink technology. Access: The resulting data are available to researchers in PPMI's repository. Purpose: The dataset may help researchers study Parkinson's biology, patient subtypes, disease progression and potential biomarkers. Impact: The resource supports prec", "date_published": "2026-08-11T12:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:849fd66286a023448d721155eb77b3e4932666b084bce0e7349369ce07939314", "url": "https://finance.yahoo.com/healthcare/articles/idexx-expands-catalyst-platform-cardiac-110000498.html", "external_url": "https://finance.yahoo.com/healthcare/articles/idexx-expands-catalyst-platform-cardiac-110000498.html", "title": "IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test", "content_text": "New test brings quantitative cardiac assessment for cats and dogs into everyday workflows WESTBROOK, Maine, August 11, 2026--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst\u2122 proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cat", "date_published": "2026-08-11T11:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "IDXX"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IDXX", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ec684ca1-5592-42c0-87f1-2957473896e9/"}]}}, {"id": "source:087d578d3f75d830d50d54bbb4f31de98eb6f9576d94fb132b7fae0ab08fa04b", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "content_text": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "date_published": "2026-08-11T08:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:c27320e8ca02985c9f1c86b98dd29b4b9a258173202b95b8fabee03750fbf62c", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "title": "Sector Update: Healthcare Stocks Gain Late Afternoon", "content_text": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-10T19:58:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:a154841a20179ab408369874e9631ab5bb694429f8d159cb1e5aa9d93a3b4a48", "url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "external_url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "title": "How Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform", "content_text": "In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S, Thermo Fisher is deepening its role in linking high-complexity diagnostics with streamlined lab workflows and more standardized ", "date_published": "2026-08-10T19:15:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:6038f22aad4fd393cbbf01648401cd7f87962e69d81d7f61d81eef7db7c5ad36", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "title": "Sector Update: Healthcare Stocks Rise in Afternoon Trading", "content_text": "Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-10T17:40:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:309a29f5c028e2baf45de118523760972e80d1f8e0c912e8ede47a96913c6a6c", "url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "title": "Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus", "content_text": "Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. economic outlook, expectations for a supportive Federal Reserve policy environment and easing concerns about inflation. Strong corporate earnings also helped reinforce confidence in the market's growth prospects. Technology and growth-oriented sectors led the advance, boosting the Nasdaq, while broader participation suppo", "date_published": "2026-08-10T12:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:cf5876587718bd1c845e6d6d2f5587edbccd20aa96ef6b42f35f990578eb1131", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "title": "Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?", "content_text": "Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher's (NYSE:DHR) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?Top Long-Term Biotechnology Stocks", "date_published": "2026-08-10T00:01:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}, {"id": "source:e5e7b866e9a346a15b2c8585660f3b529c6239b54fafe82bdc69c769e5145223", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNNmxMZUFtcURRUU0zNjl4dnZiZGRDLUYwR1dMdlNQTlJUR3BtTWFMMFZfQ01mRjJoeEY5a204Q1ptenNJeXM1NVVrSl91clhVZ1c0elB6MTlob2dramw0Zk5XRUllSW10bU1lUkpreHMzUGdMTE1oV3ZINXJLUlhmLUxBVElMTzNBVzJUcGE5a1NmeHIybjh5R3BR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNNmxMZUFtcURRUU0zNjl4dnZiZGRDLUYwR1dMdlNQTlJUR3BtTWFMMFZfQ01mRjJoeEY5a204Q1ptenNJeXM1NVVrSl91clhVZ1c0elB6MTlob2dramw0Zk5XRUllSW10bU1lUkpreHMzUGdMTE1oV3ZINXJLUlhmLUxBVElMTzNBVzJUcGE5a1NmeHIybjh5R3BR?oc=5", "title": "Thermo Fisher Scientific, Inc.: Konsensus der Analysten und Kursziel | 857209 | US8835561023", "content_text": "Thermo Fisher Scientific, Inc.: Konsensus der Analysten und Kursziel | 857209 | US8835561023", "date_published": "2024-08-06T05:22:01+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "TMOF"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMOF", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b66d93ce-7b32-438c-8d5b-6873906c6b4f/"}]}}]}